Conferences - Results from #8300

SUO 2015 - Variant Morphology in Bladder Cancer: Updates and Controversies - Session Highlights December 3, 2015

SUO 2015 Aggressive Variant Prostate Carcinomas: “Beyond Morphologic Characterization” - Session Highlights December 3, 2015

SUO 2015 - Intermediate Atypical Carcinoma: A New CRPC Entity - Session Highlights December 2, 2015

Clinical outcomes in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (ABI) stratified by prognosis October 14, 2015

The Prostate Cancer Registry: First results from an international, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC) October 14, 2015

Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective “Real Life” analysis of activity and safety October 14, 2015

ASCO - Poster: Randomized phase-2 study of sipuleucel-T with or without radium-223 in men with asymptomatic/minimally symptomatic bone-metastatic castrate-resistant prostate cancer June 18, 2015

ASCO - Poster: Radium-223 in an international early access program (EAP): Effects of concomitant medication on overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients June 11, 2015

ASCO - TROG 03.06 and VCOG PR 01-03: The "timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial - Session Highlights June 10, 2015

ASCO - A phase III protocol of androgen suppression and radiotherapy vs. AS and RT followed by chemotherapy with docetaxel and prednisone for localized, high-risk prostate cancer - Session Highlights June 9, 2015

ASCO - First-ever evidence shows adjuvant chemotherapy improves overall survival in high-risk, localized prostate cancer - Session Highlights June 4, 2015

ASCO - Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE - Session Highlights June 3, 2015

ASCO - Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration resistant prostate cancer - Session Highlights June 2, 2015

ASCO - ARAMIS: Novel oral androgen receptor inhibitor ODM-201 enters phase 3 study in nmCRPC - Session Highlights June 2, 2015

#ASCO15 - ODM-201 demonstrates high anticancer activity and favorable tolerability in the ARADES phase I/II trial in mCRPC - Session Highlights June 2, 2015

ASCO 2015 - Long-term consequences of intermittent and continuous androgen deprivation in men with metastatic prostate cancer - Session Highlights June 2, 2015

ASCO - Radium-223 provides pain relief for patients with CRPC and bone metastases - Session Highlights June 1, 2015

ASCO - Timing of radium-223 in today’s treatment landscape - Session Highlights June 1, 2015

ASCO - Now or later: Optimal timing of docetaxel for metastatic prostate cancer: Early treatment with docetaxel chemotherapy - Session Highlights June 1, 2015

ASCO - Now or later: Optimal timing of docetaxel for metastatic prostate cancer: Late treatment with docetaxel chemotherapy - Session Highlights June 1, 2015

Page 416 of 492

email news signup